Azitra is trading at $0.15, up 7.54% from the October 5 close of $0.14, with no identified company-specific announcement explaining the October 6 pre-market move.
- Azitra’s latest reported catalyst was an October 1 update that its ATR04-484 trial could proceed to Cohort 2 after a safety review; that news predates this move.
- Major U.S. stock futures are higher after a record-setting tech session, but available evidence does not establish that this caused Azitra’s gain.